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Abstract
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the deadliest tumors worldwide.
Understanding the function of gene expression alterations is a prerequisite for developing
new strategies in diagnostic and therapy. GPRC5A (RAI3), coding for a seven transmem-
brane G protein-coupled receptor is known to be overexpressed in pancreatic cancer and
might be an interesting candidate for therapeutic intervention. Expression levels of RAI3
were compared using a tissue microarray of 435 resected patients with pancreatic cancer
as well as 209 samples from chronic pancreatitis (CP), intra-ductal papillary mucinous neo-
plasm (IPMN) and normal pancreatic tissue. To elucidate the function of RAI3 overexpres-
sion, siRNA based knock-down was used and transfected cells were analyzed using
proliferation and migration assays. Pancreatic cancer patients showed a statistically signifi-
cant overexpression of RAI3 in comparison to normal and chronic pancreatitis tissue. Espe-
cially the loss of apical RAI3 expression represents an independent prognostic parameter
for overall survival of patients with pancreatic cancer. Suppression of GPRC5a results in
decreased cell growth, proliferation and migration in pancreatic cancer cell lines via a
STAT3 modulated pathway, independent from ERK activation.
Introduction
Pancreatic cancer is one of the most perilous and lethal solid malignancies and the five-year
relative survival rate, is one of the lowest for all cancers with 8% [1]. Typical alterations in the
molecular signaling include mutations in KRAS in 95% of PDACs and in tumor suppressor’s
genes like p16/CDKN2A, p53 or SMAD4 [2]. Besides these, many other changes in different
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pathways have been described, which are caused by gene mutations as well as epigenetic mech-
anisms [2, 3].
The G-protein-coupled receptor family C, member 5, group A (GPRC5A); or retinoic acid-
inducible 3 (RAI3) gene was firstly described in 1998 as a seven transmembrane helices protein
with a molecular weight of 40 kDa and its expression is regulated by all-trans-retinoic acid
(ATRA) [4]. GPRC5a is over expressed in pancreatic, breast, gastric and colon cancer, and it
has been shown that overexpression of RAI3 predict poor prognosis in hepatocellular carci-
noma [5–11]. Functional analysis of GPRC5a in different carcinomas indicated that RAI3 has
pleiotropic effects and might confer resistance to Gemcitabine in pancreatic cancer, however
the ligand of GPRC5a remains elusive [12], but GPRC5a overexpression might lead to a reduc-
tion of EGFR levels [13–16].
In this study, we investigated the expression and function of RAI3, in pancreatic cancer.
We verified the reported RAI3 RNA over-expression using immunohistochemistry and we
could show that apical RAI3 expression is an independent prognostic marker for overall sur-
vival. The siRNA mediated knock-down of RAI3 lead to proliferation and migration inhibition
via STAT3 inactivation.
Material and Methods
Tissue microarray (TMA): patient samples and immunohistochemistry
Under consideration of the appropriate guidelines, TMA were prepared and evaluated [17].
The tissue was collected from routine surgery dissections and the histological diagnosis was
confirmed by an expert histopathologist. Samples of 598 patients were collected with approval
by the ethics committee of the Technical University Dresden, University Jena and University
Regensburg for biobanking purposes and written informed consent of each patient was
obtained. Records of the informed consent are part of the biobank database. The use of the tis-
sue for TMA construction and immunohistochemical staining was approved by the ethics
committee.
Immunohistochemical staining was performed with a VENTANA BenchMark XT (Ven-
tana, Roche Diagnostics, Freiburg) system. For deparaffinization and retrieval of antigen, the
slides were heated and pretreated with CC1 (Ventana). Subsequently, peroxidase was blocked
and the incubation with RAI3 antibody (1:400, Novus Biologicals, Wiesbaden, NBP1-89743)
followed. The detection was performed using UltraView Universal DAB Detection Kit (Ven-
tana). Finally, the slides were counterstained with haematoxilin and Bluing Reagent (Ventana).
As a negative control rabbit IgG was used. The scoring of the TMA was performed by two sci-
entists (EJ, DA), independent on clinical data. Three parameters were pre-defined: the inten-
sity of the staining (ordinal scale, 0–3 points), the portion of stained ductal cells (metric scale,
0–100%, called “expression”) and the portion of strictly apical stained cells as part of all stained
ductal cells (metric scale, 0–100%, called “apical expression”). Patients were only included in
the evaluation, when minimum one TMA core was interpretable. For a TMA core with an
intensity of 0 points the expression is assessed with 0% and the apical expression is not assess-
able. The cut-off of>30% of apical stained cells were used in the univariate analysis.
Samples of 501 patients (83.8% of the samples) could be included in the analysis of
RAI3-expression. Of these were 435 of pancreatic adenocarcinoma (tumor samples), 34 of
Intraductal Papillary Mucinous Neoplasm (IPMN) and 32 of chronic pancreatitis. Normal
ductal tissue adjacent to the tumor was used for comparison in 143 samples.
Analysis of clinico-pathological and survival data were performed for 376 patients with
pancreatic adenocarcinoma and a postoperative survival time over 30 days.
RAI3 in Pancreatic Cancer
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Cell culture and transfection with small interfering RNAs
Pancreatic carcinoma cell lines MiaPaCa-2 (CRL-1420), Panc1 (CRL-1469) and AsPc-1 (CRL-
1682) were purchased from ATCC and grown in monolayer culture in a humidified atmosphere
containing 5% CO2 at 37˚C. The culture medium for MiaPaCa-2 consists of DMEM+GlutaMax
with high glucose (Thermo Fisher Scientific, Braunschweig, Germany) supplemented by 10%
fetal bovine serum (Sigma-Aldrich, Taufkirchen, Germany) and 2.5% horse serum (Thermo
Fisher Scientific). Panc1-cells were cultured in RPMI 1640 (Thermo Fisher Scientific) with 10%
fetal bovine serum (Sigma-Aldrich). For culturing AsPc-1 cells, RPMI 1640 (Thermo Fisher Sci-
entific) were used, complemented by 10% fetal bovine serum (Sigma-Aldrich), 10 mM Hepes
(Thermo Fisher Scientific), 1 mM sodium pyruvate (Thermo Fisher Scientific) and 4,5 g/l glu-
cose (B. Braun Melsungen AG, Melsungen, Germany). Primary cell lines were isolated and cul-
tivated as described by Ru¨ckert et al. [18].
The transfection with siRNA followed the protocol of Harborth et al [19]. Two different
negative controls were used, medium containing the transfection reagent (NC1) and the non-
silencing siRNA allstars (NC2; #SI03650318 Qiagen Hilden, Germany). The siRNA Eg5 [19]
positive control and the GPRC5a-siRNA (GPRC5A.1: 5’-CAACUCAAGUUUGAGCCCUUA
(dTdT)-3’; GPRC5A.6: CAGGATGTTATCGCTATTGAA)were ordered from Eurofins MWG
Operon (Ebersberg, Germany) and Qiagen respectively. Transfection was performed using Oli-
gofectamine (Thermo Fisher Scientific) with 5 x 104 cells per well, seeded one day before the
transfection, and 68,7 nM siRNA. The result of the RNA interference experiment was evaluated
after 48 or 72 hours. The determination of the life cell count was performed with a counting
chamber (Neubauer; Marienfeld, Germany) or an automated cell counter (BIO-RAD, Munich,
Germany).
Functional assays
As a assay of seeding efficiency after 72 hours of siRNA transfection cells were detached and
3.000 cells were seeded in 12-well-plates. Cells grow for seven days and stained with Coomassie
Brilliant Blue staining solution (Brillant Blau G 250, Roth, Karlsruhe, Germany). Quantifica-
tion was performed by Gene Tools Analysis software (Syngene, Cambridge, UK).
After 48 h of transfection cells were seeded in Fluoro Blok Individual Cell Inserts (Becton
Dickinson, Heidelberg, Germany) with serum-free medium. Inserts were transferred in
24-Well-plates containing complete growth medium with 20% fetal bovine serum. The cells
were allowed to migrate in a period of exactly 16 hours. The inserts were washed in PBS
(Thermo Fisher Scientific), fixed with Methanol and stained with DAPI (Sigma-Aldrich). The
distribution of migrated cells was assessed, four image sections per well photographed and
counted with Image J (Wayne Rasband, National Institutes of Health).
Quantitative RT-PCR and western blot
The isolation of RNA was performed with miRNeasy1 Mini Kit (Qiagen) and the cDNA was
synthesized with High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific)
The quantitative RT-PCR was performed with Power SYBR1 Green PCR Master Mix (Thermo
Fig 1. Expression of RAI3 in human tissue and cell lines. TMA—Immunochemistry with RAI3-Antibody in different types of pancreatic tissue.
Presentation in 20-fold magnification of A-C: Normal; D: Chronic pancreatits (CP), E: Intraductal Papillary Mucinous Neoplasm (IPMN); F—H:
Pancreatic Ductal Adenocarcinoma (PDAC). Three parameters were considered: RAI3-Intensity (I), RAI3-Expression (Ex) and Apical RAI3-Expression
(aEx); I,J: Differential expression of RAI3 mRNA respective protein in common pancreatic cell lines and primary pancreatic cell lines measured by
qRT-PCR (I) and Western Blot (J) with a conspicuously low expression in BxPc3 and PaCaDD165 in comparison to the other cell lines in the group.
(n = 3).
doi:10.1371/journal.pone.0170390.g001
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Fisher Scientific) and analyzed by 2-ΔΔCt method [20]. The housekeeping gene β-Actin was used
as reference-value. Primer sequences for amplification were β-Actin-F (5’-AAATCTGGCACCA
CACCTTC-3’), β-Actin-R (5’-AGAGGCGTACAGGGATAGCA-3’), GPRC5a-F (5’-TCTAT
GCCCCCTATTCCACA-3’)and GPRC5a-R (5’-TGCATTTGTCCCACTCTTCA-3’)(Eurofins
MWG Operon).
Cells were lysed with RIPA-buffer, gel electrophoresis was performed under reducing con-
ditions with acrylamide gels (NuPAGE Novex 4–12% Bis-Tris Gele, Thermo Fisher Scientific)
and proteins were transferred to a nitrocellulose membrane (GE Healthcare Life Science, Frei-
burg, Germany). As primary antibodies RAI3 (1:10,000, Novus Biologicals, NBP1-89743),
ERK (1:1,000, Cell Signaling #9102), phospho-ERK (1:1,000, Cell Signaling #9101) STAT3
(1:1,000, Cell Signaling #9139) and phospho-STAT3 Tyr705 (1:1,000, Cell Signaling #9145)
were used for detection. The antibodies α-Tubulin (1:5,000, Sigma-Aldrich, T9026) and
GAPDH (1:1,000, Cell Signaling, #2118) served as loading controls. Signal detection was per-
formed using ImmobilonTM Western Chemilumineszenz HRP Substrate (Merck Chemicals,
Darmstadt, Germany) and HRP-linked anti-rabbit IgG (1:1,000, Cell Signaling, #7074) or anti-
mouse IgG (1:1,000, Cell Signaling, #7076). Quantification of signals was performed by the
Gene Tools Analysis software (Syngene, Cambridge, UK).
Statistical analysis
Statistical analysis was performed with IBM SPSS1 Statistics Version 22 and Microsoft
Excel1 Version 2013. For cell culture experiments t-test was used. Within the evaluation of
the immunohistochemistry Kruskal-Wallis test, Fisher’s exact test, Mann-Whitney test,
Receiver Operating Characteristic (ROC) curve, Kaplan-Meier curve with Log-Rank test for
univariate analyses as well as a Cox regression for multivariate analysis was applied. For inter-
pretation of differences a p-value 0.05 was considered as statistically significant.
Results
In PDAC and IPMN the percentage of RAI3 expressing cells is highly elevated (median = 90%)
compared to normal (median = 40%) and CP tissue (median = 60%) and PDAC cells show
mostly a strong expression. Apical expression was detected in 100% of stained normal and CP
tissue as well as in 90% of the stained IPMNs. PDAC-tissue showed an obvious loss of apical
expression (median = 30%) (Fig 1A–1F and Fig 2A and 2B) (Kruskal-Wallis-test p<0.001 for
all parameters).
A diagnostic score to differentiate pancreatic cancer from CP or normal tissue, was calcu-
lated by addition of increasing RAI3-intensity and decreasing apical RAI3-expression dis-
played an AUC of 0.954 (p<0.001). Assuming that a value of minimum 4 (respective 5) of 6
points is typically for tumorous tissue, the diagnostic score exhibits a calculated sensitivity of
89.7% (respective 70.6%) and specificity of 94.3% (respective 98.3%) (Fig 3A and 3B).
Univariate analysis the clinic-pathological data of the 376 patients with PDAC analyzed dis-
played a significant difference (p<0.05) in survival concerning the pN-stage (regional lymph
nodes affected, histology grade, resection margin and apical RAI3 expression (Table 1).
Patients with an apical RAI3-Expression of 30% or lower showed a loss of 4 months in median
Fig 2. Intensity and Expression of RAI3 in Ductal Pancreatic Cells of different tissue types. A: Relative distribution of
RAI3-Intensity (* indicates statistically significant differences (p < 0.001) according to Fisher‘s exact test); B: Comparison of
the parameters Common Rai3-Expression and Apical Rai3-Expression (* indicates statistically significant differences
(p < 0.001) according to Mann-Whitney-Test with Bonferroni-adjustment).
doi:10.1371/journal.pone.0170390.g002
RAI3 in Pancreatic Cancer
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Fig 3. RAI3 immunohistochemistry as diagnostic and prognostic instrument. A: Definition and calculation of a diagnostic score for the presence of
a pancreatic ductal adenocarcinoma (PDAC); B: Receiver Operating Characteristic (ROC) curve for the diagnostic score using for distinction of PDAC
from Normal or Chronic Pancreatitis (CP) tissue (Sensitivity and specificity were calculated for two exemplary cut-off-points); C: Univariate Kaplan-Meier
analysis (statistically significant differences between apical expression over 30% and less (p = 0.017) according to Log-Rank-test).
doi:10.1371/journal.pone.0170390.g003
RAI3 in Pancreatic Cancer
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Table 1. Univariate analysis of clinico pathological variables of the 376 patients with pancreatic cancer analyzed on the TMA.
Variables N % OS (months) p-Value (Log-Rank)
Total cohort 376 100 16.49
Age (at OP-time)
Mean (years) 64.0 ± 0.51
Median (years) 66
Range (years) 33–84
to 65 years 176 46.8 18.10 0.120
over 65 years 200 53.2 15.11
Gender
male 202 53.7 17.15 0.791
female 174 46.3 15.18
Origin
Jena 96 25.5 18.10 0.962
Regensburg 81 21.5 14.55
Dresden 199 52.9 16.49
T stage
T1/2 57 15.2 19.65 0.875
T3/4 319 84.8 16.13
N stage
negative 115 30.6 22.93 0.005
positive 261 69.4 15.60
M stage
negative 301 80.0 17.28 0.236
positive 15 4.0 11.66
unknown 60 16.0 -
Histology grade
G1/2 179 47.6 21.03 <0.001
G3/4 197 52.4 13.93
Resection margin
R0 277 73.7 19.15 0.007
R1/2 99 26.3 12.88
Adjuvant therapy
no 252 67.0 15.70 0.085
yes 124 33.0 19.88
RAI3-Intensity
negative to moderate 66 17.6 19.15 0.926
strong 310 82.4 16.23
RAI3-Expression
< 90% 106 28.2 15.60 0.338
 90% 270 71.8 16.79
Apical RAI3-Expression
> 30% 171 44.8 19.15 0.017
 30% 205 53.7 15.18
Presentation of the investigated 376 patients with pancreatic adenocarcinoma, including their clinicopathological data and the results of univariate analysis.
P-values are calculated by Log-Rank-test and statistically significant differences (p<0.05) in overall survival (OS) subsequently marked by bold p-values.
doi:10.1371/journal.pone.0170390.t001
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survival time (p = 0.017, Fig 3C). Cox-regression analysis revealed that apical RAI3-expression
is a independent prognostic factor for the survival of the patients (Table 2, RR: 1.37; p< 0.05).
To elucidate the role of RAI3 further we first compared expression levels in pancreatic can-
cer cell lines by Western blot and quantitative RT-PCR. The immortalized human ductal pan-
creatic epithelial (HDPE) cell line [21] showed only negligible expression of RAI3 protein or
GPRC5A mRNA expression, whereas pancreatic cancer lines displayed highly variable but
detectable over-expression (Fig 1G and 1H).
In siRNA based knock-down experiments both GPRC5A-siRNAs led to a significant decrease
in cell number in Panc1, MiaPaCa-2 cells and AsPc-1 cells (P<0.05) compared to the negative
control (Fig 4A) and were able to suppress RAI3 expression (Fig 4B). Moreover, colony forming
was impaired in siRNA treated cells in MiaPaCa-2, Panc1 and AsPc-1 cells (P<0.01). RAI3 sup-
pression inhibited colony forming in MiaPaCa-2 cells by 69%, in Panc1 by 83% and in AsPc-1 by
51% (Fig 5A and 5B). Furthermore, the treatment with the GPRC5a-siRNA showed a large effect
on the migratory ability of the cells, since only 5.0% [±2.5%] of MiaPaCa-2, 38.9% [±10.3%] of
Panc1 and 31.0% [±16.0%] of AsPc-1 migrated compared to the control (Fig 5C and 5D).
A central pathway that influences the cell proliferation and migration is the Ras/Raf/MEK/
ERK pathway. Analysis of the proteins ERK 1/2 and their activating phosphorylation sides
phospho-ERK 1/2 (Thr202/Thr204) showed no alteration, but RAI3 mRNA suppression
resulted in a reduced level of the phosphorylated form (Tyr705) of STAT3 in all cell lines ana-
lyzed (Fig 6).
Discussion
The results in TMA show clearly, that RAI3/GPRC5a is over-expressed in PDAC in compari-
son to normal pancreas or CP tissue. Interestingly, in IPMN, a cystic neoplasm that is consid-
ered to be a precursor lesion for pancreatic cancer, also high intensity and expression levels
ofRAI3 were observed. Compared to other tissues the loss of apical staining in PDACs was
revealed as an independent parameter for the overall survival of patients with pancreatic carci-
noma. A possible background for this is the increasing loss of cell polarity and architecture
Table 2. Multivariate Cox proportional hazard model for different variables.
Variables Hazard Ratio 95% CI Significance
Step 1
Histology Grade (high grade vs. low grade) 1.514 1.172–1.957 0.002
Step 2
Histology Grade (high grade vs. low grade) 1.570 1.211–2.036 0.001
Adjuvant Therapy (yes vs. no) 0.753 0.574–0.987 0.040
Step 3
N-stage (positive vs. negative) 1.382 1.039–1.838 0.026
Histology Grade (high grade vs. low grade) 1.501 1.154–1.952 0.002
Adjuvant Therapy (yes vs. no) 0.727 0.553–0.954 0.022
Step 4
N-stage (positive vs. negative) 1.447 1.084–1.931 0.012
Histology Grade (high grade vs. low grade) 1.354 1.027–1.784 0.032
Adjuvant Therapy (yes vs. no) 0.705 0.537–0.928 0.012
Apical RAI3-Expression (30% vs. >30%) 1.371 1.040–1.806 0.025
Presentation of the results of multivariate analysis by cox regression. Statistically significant independent parameters for overall survival are N-Stage,
Histology Grade, Adjuvant Therapy and Apical RAI3-Expression.
doi:10.1371/journal.pone.0170390.t002
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with the dedifferentiation of the tumors. This could be detected earlier by immunohistochem-
istry than by conventional methods as seen with other marker [22].
The overexpression of RAI3 in pancreatic cancer could be confirmed in the comparison of
mRNA and protein-levels in different cell lines. Thereby, RAI3 expression seems to seems to
suggest a connection with the phenotypes respectively genotypes of the cell lines. The two cell
lines HPAF and AsPc-1, which have a high RAI3 protein level, were isolated from ascites [23].
BxPc3 and PaCaDD 165, which have a low GPRC5A mRNA and protein level, show both a
KRAS wild type [24] indicating that RAI3 expression increases with malignancy of a tumor. A
previous described connection between the expression of RAI3 and an alteration of p53 in
breast carcinoma cell lines [25] could not be confirmed, since cell lines with a high GPRC5A
mRNA expression like PaCaDD 161 are p53 wild type and cell lines with a p53 mutation like
Fig 4. Effect of treatment with GPRC5a-siRNA over 72 hours. A: Number of living cells in negative
controls (NC; 1: Medium, 2: non-sense-siRNA), positive control (PC; eg5-siRNA) and knock-down with two
different GPRC5a-siRNA (RAI3_A and RAI3_B). Statistically significant differences in t-test are marked with *
for P-Value < 0.001 and ** for P-Value < 0.05; B: Western blot and quantitative real time PCR with RAI3
antibody confirms the successful knock-down using siRNA (for functional analysis the GPRC5A.1 siRNA was
chosen) (S1 Fig). (n = 5).
doi:10.1371/journal.pone.0170390.g004
RAI3 in Pancreatic Cancer
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BxPC3 display low GPRC5A level. However, the regulation of RAI3 might be dependent on
the type of p53 mutation and might be co regulated by other factors like proteins of the retinoic
acid receptor family [4, 26].
Our results of RNA-interference experiments indicates, that GPRC5a has some function in
promoting cell growth, proliferation and migration by reducing the crucial phosphorylation of
STAT3 at the position Tyr705, whereas the KRAS/MAPK signaling remains mostly
unchanged.
This is consistent with the results of previous published experiments with the breast
cancer cell lines T47D and MCF7, which showed a growth-inhibiting effect of GPRC5A-
siRNA [14].
An alteration in proliferation ability might also influence the migration ability of the cells
and could cause an ostensible effect on migration. However, in Panc1-cells, we demonstrated a
high effect on migration ability, whereby the influences on proliferation were still low. There-
fore, we assume a proliferation-independent effect of GPRC5A knock-down on migration
ability of the PDAC-cells, which is dependent on the cellular context.
Nevertheless, we could demonstrate high overexpression of GPRC5a in PDACs. Our data
lead to the suggestion, that RAI3 is an epigenetic regulated gene PDACs with oncogenic
effects, which could be used for diagnostic and prognostic aspects. Since, GPRC5a is located in
cell membrane; it represents a potential therapeutic target.
Fig 5. Effect of siRNA based knock-down on the colony formation and migration of pancreatic cancer cell lines. A: Examples of the results of
typical colony forming assays over 7 days after siRNA-treatment; B: Growth area compared to NC1 (statistically significant difference between RAI3 and
NC2 is demonstrated by * for P<0.01 and ** for P<0.001 performed by t-test); C: Typical images of migrated cells in negative control (NC) and knock-
down with GPRC5a siRNA (RAI3) in different cell lines; D: Number of migrated cells after 48 hour siRNA-treatment and subsequently 16 hours migration
assay (* indicates statistically significant differences (P<0.05) in t-test between the negative control with non-sense-siRNA (NC) and the knock-down
with GPRC5a-siRNA (RAI3)). (n = 3).
doi:10.1371/journal.pone.0170390.g005
Fig 6. Western Blot analysis of different pathways were tested for alteration in knock-down with GPRC5A
siRNA in comparison to negative control. Phosphorylation of STAT3 at Tyr705 is reduced in knock-down of all
three cell lines, whereas Phospho-ERK is not changed significantly (see S2 Fig for original Western blot images).
(n = 3).
doi:10.1371/journal.pone.0170390.g006
RAI3 in Pancreatic Cancer
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Supporting Information
S1 Fig. Results of GPRC5a knockdown in three pancreatic cancer cell lines measured by
quantitative real time PCR from total RNA.
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S2 Fig. Original Western blot images for the analysis of pathway perturbation.
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